In this study, we demonstrate that inhibition of ERK5 is a feasible approach to overcome resistance to anti-HER2 agents and propose ERK5 as a promising novel therapeutic target to increase the antitumor action of existing HER2-blocking strategies for treating breast cancer. Here, ERBB2 is linked to breast carcinoma.